These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38988285)

  • 1. Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects.
    Liu J; Zhao Q; Zhai Y; Wu X; Kai J; Ruan J; Wu M; Wu M; Zhou Z; Yan Y; Wu JJ; Qiu Y
    Expert Opin Investig Drugs; 2024 Aug; 33(8):867-876. PubMed ID: 38988285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
    Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
    Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
    Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
    Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
    Li X; Liu Y; Wang M; Gao L; Liu J; Zhang H; Wu M; Chen H; Lou J; Wang J; Chen J; Geng G; Ma Z; Ding Y
    Lancet Infect Dis; 2024 Jun; 24(6):650-664. PubMed ID: 38359854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.
    Jin C; Yi C; Chen K; Liang H
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
    Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
    Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.
    Zhou XJ; Horga A; Puri A; Winchester L; Montrond M; Pietropaolo K; Belanger B; Fletcher CV; Hammond J
    J Antimicrob Chemother; 2024 Jun; 79(6):1423-1431. PubMed ID: 38708557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
    Xie P; Abildlund MT; Bækdal TA; He X; Lyauk YK; Patted URH; Ning Z; Shi A
    Diabetes Obes Metab; 2024 Aug; 26(8):3068-3077. PubMed ID: 38808476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
    Zhao N; Xie R; Zhao X; Zhao H; Jia B; Zhang Y; Luo L; Huang Z; Li J; Wang X; Yan H; He B; Xie H; Ren Q; Cui Y
    Clin Drug Investig; 2019 Jul; 39(7):671-681. PubMed ID: 31079356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
    Li X; Haranaka M; Li H; Liu P; Chen H; Klein S; Reif S; Francke K; Friedrich C; Okumura K
    Clin Pharmacokinet; 2024 Jun; 63(6):901-915. PubMed ID: 38907175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study.
    Wang H; Liu H; Liu M; Wang W; Zhu L; Huang H; Hu P; Jiang J
    Eur J Pharm Sci; 2017 Mar; 100():87-93. PubMed ID: 28057550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
    Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
    Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants.
    Li S; Wangqin R; Meng X; Li H; Wang Y; Wang H; Laskowitz D; Chen X; Wang Y
    Clin Ther; 2022 May; 44(5):744-754. PubMed ID: 35562205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
    Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.